Who are Lipofundin N 20%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): OLIVE OIL, SOYBEAN OIL, SMOFlipid + Omegaven, ClinOleic, ClinOleic + Omegaven, Lipofundin MCT 20%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lipofundin-n-20.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lipofundin N 20% — Competitive Intelligence Brief

Lipofundin N 20% (Lipofundin N 20%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid emulsion; parenteral nutrition component. Area: Nutrition support; Critical care.

marketed Lipid emulsion; parenteral nutrition component Nutrition support; Critical care Small molecule Live · refreshed every 30 min

Target snapshot

Lipofundin N 20% (Lipofundin N 20%) — B. Braun Melsungen AG. Lipofundin N 20% is a lipid emulsion that provides essential fatty acids and calories for parenteral nutrition in patients unable to eat or absorb nutrients orally.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Approval / PDUFA
Lipofundin N 20% TARGET	Lipofundin N 20%	B. Braun Melsungen AG	marketed	Lipid emulsion; parenteral nutrition component
OLIVE OIL	OLIVE OIL		marketed	Lipid Emulsion [EPC]	2013-01-01
SOYBEAN OIL	SOYBEAN OIL		marketed	Lipid Emulsion [EPC]	1982-01-01
SMOFlipid + Omegaven	SMOFlipid + Omegaven	General University Hospital, Prague	marketed	Lipid emulsion / Parenteral nutrition supplement
ClinOleic	ClinOleic	Shanghai Jiao Tong University School of Medicine	marketed	Lipid emulsion for parenteral nutrition
ClinOleic + Omegaven	ClinOleic + Omegaven	General University Hospital, Prague	marketed	Intravenous lipid emulsion
Lipofundin MCT 20%	Lipofundin MCT 20%	B. Braun Melsungen AG	marketed	Lipid emulsion; parenteral nutrition supplement

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid emulsion; parenteral nutrition component class)

B. Braun Melsungen AG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipofundin N 20% — Competitive Intelligence Brief. https://druglandscape.com/ci/lipofundin-n-20. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab